Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis... |
|
Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC
In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!
STATEMENT OF NEED
Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the Unite... |
|
Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs
STATEMENT OF NEED
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ... |
|
Putting the Freeze on Cold Agglutinin Disease
STATEMENT OF NEED
Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpitations, and shortness of breath caused by the anemia; jaundice caused by degradation of hemoglobin i... |
|
Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View
STATEMENT OF NEED
Immune checkpoint inhibitors, which alter immune regulatory pathways and promote cell-mediated destruction of tumor cells, have revolutionized the treatment of cancer in recent years, with numerous therapeutic agents approved and several targets under investigation (Chennamadhavuni et al, 2022). However, up to 90% of patients receiving immune checkpoint inhibitors experience immune-related adverse events, which can affect a wide variety of organ systems and can occur at any ... |
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
|
Tracking and Treating Uveitic Macular Edema: A Difficult Dilemma
Uveitic macular edema (UME) has a wide variety of causes. If not appropriately treated, it eventually causes damage to the photoreceptors in the macula, resulting in vision-threatening complications like macular ischemia or macular hole formation. Corticosteroids are the first-line treatment for uveitic inflammation and UME. However, they are not generally considered to be appropriate for long-term treatment due to adverse effects, including increased intraocular pressure and cataract in local... |
|
Tracking and Treating Uveitic Macular Edema: A Difficult Dilemma
Uveitic macular edema (UME) has a wide variety of causes. If not appropriately treated, it eventually causes damage to the photoreceptors in the macula, resulting in vision-threatening complications like macular ischemia or macular hole formation. Corticosteroids are the first-line treatment for uveitic inflammation and UME. However, they are not generally considered to be appropriate for long-term treatment due to adverse effects, including increased intraocular pressure and cataract in local... |
|
Pathways to Developing Personalized Treatment Regimens for Patients with Advanced Melanoma
No two patients with advanced melanoma are the same and tailoring treatment is vital. Immerse yourself in this interactive “choose your path” digital algorithm with expert perspectives to assist with the application of new guidelines and treatment options to optimize therapy.
Do you have questions about treating patients with advanced melanoma? Do you wonder…
• When to use immune checkpoint inhibitors (ICIs), and in which combinations?
• How to select among the growing number o... |
|
Real-World Perspectives in Managing CLL Treatment
Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances ... |
|
Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer: Strategies for Improving Care and Outcomes
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
In recent years, the emergence of novel therapeutic agents has led to improved outcomes for patients with advanced and/or platinum-resistant ovarian cancer. Yet, even with improved treatment options, oncology teams in rural and underserved settings are challenged to provide ... |
|
Multidisciplinary Strategies to Prevent Hospitalization in Patients with Worsening Heart Failure
Despite guideline-directed medical therapy, many patients with heart failure (HF) with reduced ejection fraction continue to experience worsening HF and hospitalizations. As such, it is incumbent upon clinicians to improve familiarity and competence with available therapies and clinical trial data that may guide patient selection to individualize and optimize therapy for patients with HF. In this interactive infographic, clinicians can access real-world strategies and expert insights to improv... |
|
Diabetes Comorbidities and Complications - LIVE STREAMING
This comprehensive course, which is among the highest-rated Harvard Medical School CME courses, provides education and updates to optimize your care of patients with diabetes and these conditions:
• Obesity
• Cardiovascular Disease
• Heart Failure
• Coronary Artery Disease
• Cerebrovascular Disease
• Hypertension
• Hyperglycemia
• Hypoglycemia
• Dyslipidemia
• Metabolic-Associated Fatty Liver Disease
• Chronic Kidney Disease
Sessions are led by experts in thes... |
|
Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage
Jason J. Luke, MD, discusses the impact of evolving therapies on the disease burden, survival, and treatment tolerability for patients with cutaneous melanoma. Recent clinical trial results and guideline updates for both perioperative and metastatic cutaneous melanoma are reviewed. To provide patient-centric care, Dr. Luke shares his expert insights and recommendations for individualizing treatment selection and sequencing, as well as providing supportive care and adverse event management. |
|
PARP Inhibition as Ovarian Cancer Maintenance Therapy: Improving Patient Outcomes as a Multidisciplinary Team
Ovarian cancer (OC) is often diagnosed at an advanced stage and has generally poor survival rates¬"even after aggressive surgical management and chemotherapy. Without maintenance therapy, approximately 70% of patients relapse within 3 years of treatment. Recent clinical trials of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors have demonstrated substantial efficacy as maintenance therapy for OC patients. Additionally, clinical evidence suggests that daily monitoring of pati... |
|
Case Studies in HIV Resistance Testing and Treatment " Experienced Patients
Educational Need:
Through a series of patient cases, participants will explore the complexities of managing HIV infection in patients who have been treated with multiple different HIV regimens. Participants will engage in real-life case studies that will provide valuable insight into the intricacies of HIV treatment and resistance testing. Our faculty educators will discuss commonly encountered challenges faced by the care team and their treatment-experienced patients with HIV and offer real... |
|
Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies
The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized educa... |
|
Clinical Questions in Cardiology: Using Glucagon-like Peptite-1 Receptor Agonists
The glucagon-like peptide-1 receptor agonist (GLP-1RA) class of medications has become an important option for treating patients with type 2 diabetes mellitus (T2D). Cardiovascular outcome trials also show that selected GLP-1RAs exert beneficial cardiovascular benefits in patients with and without T2D. In this activity, case studies commonly encountered in cardiology practice are utilized to prompt reflection on opportunities for reducing cardiovascular risk. Drawing on seminal research and th... |
|
Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma
ACTIVITY DESCRIPTION
Though treatment advances have improved outcomes for most patients, MM remains an incurable disease characterized by continuous relapse. However, the treatment landscape for relapsed/refractory MM (RRMM) has expanded in recent years, and patients who relapse and/or become refractory to initial therapies are benefiting from the increasing availability of a diverse range of novel agents, including B-cell maturation antigen (BCMA)"targeted immunotherapies. These agents ... |
|
Executive Functioning in Adults
Executive Functioning in Adults is a 3-hour online continuing education (CE/CEU) course that provides strategies to help adults overcome executive functioning deficits.
Executive functioning (EF) is an umbrella term for the various complex cognitive processes that are responsible for cognitive control of thoughts and actions that are necessary to maintain goal‐directed behavior in pursuit of the attainment of future goals (Holst & Thorell, 2018). Executive skills allow one to organize the... |
|
Therapy Tidbits – Spring 2021
Therapy Tidbits – Spring 2021 is a 1-hour online continuing education (CE) course comprised of select articles from the Winter 2021 issue of The National Psychologist, a private, independent, quarterly newspaper intended to keep psychologists informed about practice issues. The articles included in this course are:
Congress Throws a Wrench in Medicare Telehealth Rules – Identifies Section 123 of the Consolidated Appropriations Act and explains the impact this bill will have on telehealt... |